Dyne Therapeutics Shows FORCE Platform Can Cross Blood-Brain Barrier in Primates
Event summary
- Dyne Therapeutics will present preclinical data at the 2026 ASGCT Annual Meeting showing its FORCE platform can cross the blood-brain barrier and achieve ~75% MAPT RNA knockdown in nonhuman primates.
- Two conjugates (Conjugate 1 using the clinically validated FORCE Fab, Conjugate 2 with an optimized Fab) demonstrated robust CNS activity across multiple brain regions.
- Presentation scheduled for May 13, 2026, by Susana Correia, Ph.D., Director of Research at Dyne.
The big picture
Dyne's FORCE platform expansion into CNS delivery represents a strategic pivot that could unlock new therapeutic markets beyond its current neuromuscular disease focus. The ability to cross the blood-brain barrier with siRNA payloads positions Dyne as a potential leader in developing treatments for tauopathies like Alzheimer's disease, where effective CNS delivery remains a major challenge.
What we're watching
- Pipeline Expansion
- Whether Dyne can efficiently allocate resources to develop neurological indications while maintaining progress in its core neuromuscular disease programs.
- Clinical Validation
- The pace at which optimized FORCE platform variants advance toward human trials for CNS applications.
- Competitive Positioning
- How this data positions Dyne against competitors developing blood-brain barrier crossing technologies for neurological diseases.
Related topics